Section 840.115  Methods of Reporting Cancer Registry Information

 

a)         All patients identified at a reporting facility, whether as an inpatient or outpatient, who meet one of the three following criteria are reportable to the Registry:

 

1)         Patients with a newly diagnosed cancer who have, within six months after diagnosis, received cancer-directed treatment or refused treatment.

             

2)         Patient with cancer diagnosed through autopsy.

 

3)         Patient diagnosed and receiving all first course treatment elsewhere and now receiving cancer-directed treatment at the reporting facility.

 

b)         A patient is considered to have a malignant neoplasm when a licensed physician or dentist indicates that he/she does.  Otherwise, the following terminology, when applied to a malignancy, shall be interpreted as indicating involvement by a cancerous tumor:

 

1)         apparent,

 

2)         appears to,

 

3)         comparable with,

 

4)         compatible with,

 

5)         consistent with,

 

6)         favors,

 

7)         malignant appearing,

 

8)         most likely,

 

9)         presumed,

 

10)         probable,

 

11)         suspected,

 

12)         suspicious for, and

 

13)         typical of.

 

c)         The following terminology, when applied to a malignancy without additional information, shall be interpreted as indicating non-involvement by a cancerous tumor:

 

1)         cannot be ruled out,

 

2)         equivocal,

 

3)         possible,

 

4)         potentially malignant,

 

5)         questionable,

 

6)         rule out,

 

7)         suggests, and

 

8)         worrisome.

 

d)         Determination of whether or not a given primary tumor is reportable shall be made by reference to the morphology codes (M-codes) of the International Classification of Diseases for Oncology (ICD-O).

 

e)         The specified cases of tumorous or precancerous diseases that shall be reported to the Registry are:

 

1)         benign intracranial tumors, and

 

2)         other conditions that the facility wishes to report.

 

f)          Cases of basal or squamous cell neoplasms of the skin shall be reported only when located in the following areas:  penis, scrotum, anus, eyelid, and muco-cutaneous junctions of the lips, labia and vulva.

 

g)         There are two mechanisms by which a reporting facility can report cancer cases. 

 

1)         Option #1.  Electronic Reporting:  Facilities that submit electronically shall submit the report in the North American Association of Central Cancer Registries (NAACCR) data exchange format, using the version specified by the Registry (see Section 840.20).  Supporting text documentation that is sufficient to support the diagnosis, stage, and treatment should be included for each case submitted.

 

2)         Option #2.  Manual Reporting:  Facilities that submit in manual format should use the forms provided by the Registry.  These facilities shall code all fields on the manual report form.  Supporting text documentation that is sufficient to support the diagnosis, stage, and treatment should be included for each case submitted.

 

h)         All reporting facilities are responsible for complete casefinding, which means identifying all first time reported cancer patients and completing an incidence report form for the Registry.  To achieve complete case ascertainment, the following sources should be reviewed as they apply:  Medical Record Disease Index (ICD-CM) or CPT Coding Index; pathology reports; cytology reports; autopsy reports; surgery and/or outpatient logs; radiation therapy and/or oncology clinic logs and appointment books; and diagnostic X-rays, nuclear medicine reports, and/or other imaging techniques.

 

1)         Any patient's clinical record identified with any of the following ICD-9-CM Diagnosis or Procedure Codes by the Medical Record Department shall be reviewed for reportability to the Registry:

 

Diagnosis Codes                       Diagnosis (in preferred ICD-O-3 terminology)

 

A)        042                              AIDS with malignancy

 

B)        140.0-208.9                 Malignant neoplasms

                       

                                    C)        203.1                           Plasma cell leukemia (9733/3)

 

D)        205.1                           Chronic neutrophilic leukemia (9963/3)

 

E)         225.0-225.4                 Benign intracranial and CNS neoplasms

225.8-225.9

227.3-227.4

 

F)        230.0-234.9                 Carcinoma in situ

 

G)        237.0-237.1                 Borderline intracranial and CNS neoplasms

            237.5-237.6

            237.7, 237.9

 

H)        238.4                            Polycythermia erra (9950/3)

 

I)         238.6                            Solitary plasmacytoma (9731/3)

 

J)         238.6                            Extramedullary plasmacytoma (9734/3)

 

K)       238.7                            Chronic Myeloproliferative disease (9960/3)

 

L)        238.7                            Myelosclerosis with myeloid metaplasia (9961.3)

 

M)       238.7                            Essential thrombocythemia (9962/3)

 

N)       238.7                            Refractory cytopenia with multilineage displasia (9985/3)

 

O)       238.7                            Myelodisplastic syndrome with 5q-syndrome (9986/3)

 

P)        238.7                            Therapy related myelodisplastic syndrome (9987/3)

 

Q)       239.0-239.9                 Neoplasms of unspecified behavior

 

R)        273.2                            Gamma heavy chain disease; Franklin's disease

 

S)        273.3                            Waldenstrom's macroglobulinemia

 

T)        273.9                            Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes)

 

U)        284.9                            Refractory anemia (9980/3)

 

V)        285.0                            Refractory anemia with ringed sideroblasts (9982/3)

 

W)       285.0                            Refractory anemia with excess blasts (9983/3)

 

X)        285.0                            Refractory anemia with excess blasts in transformation (9984/3)

 

Y)        288.3                            Hypereosinophilic syndrome (9964/3)

 

Z)        289.8                            Acute myelofibrosis (9932/3)

 

AA)     V07.8                           Other prophylactic chemotherapy (screen carefully for miscoded malignancies)

 

BB)     V07.8                           Other specified prophylactic measures

 

CC)     V10.0-V10.9                Personal history of malignant neoplasm (review these for recurrences, subsequent primaries and/or subsequent treatment)

 

DD)     V58.0                           Admission for radiotherapy

 

EE)      V58.1                           Admission for chemotherapy

 

FF)      V66.1                           Convalescence following radiotherapy

 

GG)     V66.2                           Convalescence following chemotherapy

 

HH)     V67.1                           Radiation therapy follow-up

 

II)        V67.2                           Chemotherapy follow-up

 

JJ)       V71.1                           Observation for suspected malignant neoplasm

 

KK)    V76-V76.9                   Special screening for malignant neoplasm

 

LL)      92.21-92.29                 Therapeutic radiology and nuclear medicine

 

MM)    92.21-92.29                 Injection or infusion of cancer

                                                 chemotherapeutic substance

 

2)         All pathology and cytology reports from the facility with a positive morphologic diagnosis of cancer shall be reviewed for reportable neoplasms, including reports on inpatient and outpatient surgical resections and biopsy specimens, bone marrow biopsies, cytology specimens and autopsies.

 

3)         Any conflict of interpretation of cancer incidence shall defer to the clinician's determination.

 

i)          All reporting facilities shall submit the report forms on a monthly basis.

                       

(Source:  Amended at 31 Ill. Reg. 12207, effective August 2, 2007)